ROMAZICON
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ROMAZICON (ROMAZICON).
Competitive antagonist at the GABA-A receptor benzodiazepine binding site, reversing benzodiazepine effects.
| Metabolism | Hepatic metabolism via hydrolysis to inactive metabolites; major metabolite is a carboxylic acid derivative. |
| Excretion | Renal: >90% as metabolites, <1% unchanged; biliary/fecal: minor |
| Half-life | Terminal half-life 40-80 min; clinically repeated doses may be needed due to shorter duration than benzodiazepines |
| Protein binding | ~66% bound to serum albumin |
| Volume of Distribution | 0.8-1.0 L/kg; indicates moderate tissue distribution |
| Bioavailability | IV: 100% |
| Onset of Action | IV: 1-2 minutes; peak effect within 6-10 minutes |
| Duration of Action | Approximately 1-2 hours (reversal of sedation); may be shorter than long-acting benzodiazepines, requiring repeat dosing |
0.2 mg IV over 15 seconds, repeated at 1-minute intervals up to 1 mg; may repeat after 20 minutes if needed.
| Dosage form | INJECTABLE |
| Renal impairment | No adjustment required for renal impairment. |
| Liver impairment | Reduced clearance in hepatic impairment; consider dose reduction and slow administration; no specific Child-Pugh guidelines. |
| Pediatric use | Neonates and infants: 0.01 mg/kg IV (max 0.2 mg) at 1-minute intervals up to 1 mg. Children: 0.02 mg/kg IV (max 0.2 mg) at 1-minute intervals up to 1 mg. |
| Geriatric use | Initiate with 0.1 mg IV; titrate cautiously due to increased sensitivity and prolonged elimination. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ROMAZICON (ROMAZICON).
| Breastfeeding | Unknown if excreted in human milk. M/P ratio not available. Caution advised; consider risk-benefit. |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. Animal studies have not shown evidence of teratogenicity. Risk cannot be excluded; use only if clearly needed. First trimester: unknown risk. Second and third trimesters: no specific fetal risks identified, but benzodiazepine receptor antagonists may induce withdrawal in neonates exposed to benzodiazepines. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
["Known hypersensitivity to flumazenil or benzodiazepines","Severe cyclic antidepressant overdose (risk of seizures)","Patients receiving benzodiazepines for life-threatening conditions (e.g., status epilepticus, increased intracranial pressure)"]
| Precautions | ["Seizures, particularly in patients with epilepsy or mixed overdose (e.g., tricyclic antidepressants)","Hypoventilation may recur due to short duration of flumazenil vs. long-acting benzodiazepines","Panic reactions in benzodiazepine-dependent patients"] |
Loading safety data…
| Monitor maternal vital signs and level of consciousness. Fetal heart rate monitoring if used near term due to potential for neonatal withdrawal. |
| Fertility Effects | No data on fertility effects in humans. Animal studies have not shown impaired fertility. |